WASHINGTON — The Senate will vote this week on a key legislative priority for the pharmaceutical industry and the Food and Drug Administration, according to three key senators.

The package spells out how much drug and device makers pay the FDA to fund the agency’s oversight and approval processes, called user fees. The current contracts expire at the end of September, and the agency has said a new agreement is critical to its ability to continue to pay thousands of staffers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy